Dr. Amar Sethi joined VivoSim in November of 2025. He is a physician–scientist and biotechnology executive with 30 years of experience in clinical development, translational medicine, and biomarker innovation. His career is defined by advancing complex therapies through rigorous clinical strategy, science-driven execution, and creation of long-term value for patients and investors. Before joining Vivosim, Dr. Sethi served as Vice President of Clinical Science at Omeros, where he directed protocol design, regulatory engagement, and clinical data strategy across multiple programs in complement-mediated diseases. He also built internal biomarker capabilities to strengthen mechanistic understanding and expand pipeline opportunities. Previously, as President & Chief Medical Officer of Pacific Biomarkers, he guided company strategy, scientific operations, and P&L oversight, driving substantial revenue growth and contributing to the company’s successful acquisition. Earlier roles strengthened his foundation in translational medicine, immunology, clinical assay development, and laboratory operations, providing the scientific and operational depth that underpins his later success in clinical leadership. Dr. Sethi holds an M.D. and Ph.D. and has authored numerous publications and textbook chapters in clinical chemistry and biomarker science.
Tony Lialin
Tony Lialin joined VivoSim as Chief Commercial Officer in August 2025. A 25+ year commercial leader in genomics, diagnostics, bioinformatics, and imaging, Tony has built global sales teams, closed transformative pharma partnerships, and delivered $10M+ in startup revenue leading to four acquisitions. At Illumina, he closed the company’s largest-ever $157M PO and managed a $403M portfolio across GRAIL, Natera, and AncestryDNA. Previously, he held senior roles at Invivoscribe as Chief Commercial Officer, Oxford Nanoimaging as VP Sales & Customer Success, Loop Genomics as Chief Commercial Officer, Illumina as Executive Strategic Account Manager, and Agilent Technologies. He will lead Sales, Marketing, Partnerships,and Customer Success at VivoSim. He holds a B.A. in Molecular, Cellular & Developmental Biology from the University of California, Santa Cruz.
Norman Staskey
Mr. Staskey is currently under agreement with Danforth Advisors, LLC and is a seasoned executive with significant experience in managing and leading teams as well as overseeing the financial and operational responsibilities of private and publicly traded life sciences companies. He has served as a Senior Director of Danforth since May 2021. Mr. Staskey has served as the Chief Financial Officer of Azitra, Inc. since October 2022. From September 2014 to May 2021, Mr. Staskey was employed by EY (formally Ernst & Young), most recently as a managing director in EY’s Financial Accounting and Advisory services practice. Mr. Staskey received his B.S. of Business Administration from Cleveland State University and is a Certified Public Accountant in the State of Ohio.
Keith Murphy
Keith Murphy, our Executive Chairman directly overseeing all operations, is also CEO and Founder of Viscient Bio, Inc., and a serial entrepreneur and investor in biotech. Prior to co-founding Viscient Biosciences, Mr. Murphy founded Organovo Inc., in 2007 and took it public in 2012, leading it to become the world’s premier 3D bioprinting company. He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and pharma corporate partnerships to a peak valuation over $1B. Organovo successfully developed a Crohn’s disease drug candidate it sold to Eli Lilly in 2025 prior to Phase 2 studies. Prior to Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($46B+ annual sales). Prior to Amgen, he played a key role at Alkermes (NASDAQ:ALKS) in the successful development of once-monthly human growth hormone (hGH) in partnership with Genentech. He holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves as co-chair of the Board of No Patient Left Behind, a national non-profit influential in drug pricing policy to achieve broad patient access in the USA.
